|
03 Jul 2018 |
Neovacs announces the results of its phase IIb study for IFNalpha kinoid in the treatment of lupus which allows to proceed with the clinical development into phase III
|
|
27 Jun 2018 |
Inovio’s MERS Vaccine Generates High Levels of Antibodies and Induces Broad-based T Cell Responses in Phase 1 Study
|
|
21 Jun 2018 |
Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combination with Regeneron’s PD-1 Inhibitor
|
|
21 Jun 2018 |
AIVITA Biomedical Announces U.S. Food and Drug Administration Clearance of IND for Phase II Glioblastoma Multiforme Trial
|
|
20 Jun 2018 |
OncBioMune to Commence Phase 2 Trial of ProscaVax for Early Stage Prostate Cancer Patients
|
|
14 Jun 2018 |
AIVITA Biomedical Randomizes First Patient in Phase II Ovarian Cancer Trial
|
|
11 Jun 2018 |
Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens
|
|
11 Jun 2018 |
Vical Reports Phase 2 Trial of HSV-2 Therapeutic Vaccine Did Not Meet Primary Endpoint
|
|
08 Jun 2018 |
Aduro Biotech Announces Initiation of Phase 1b Clinical Trial in Non-Small Cell Lung Cancer under Janssen Strategic Partnership for ADU-214 in Combination with Nivolumab
|
|
05 Jun 2018 |
Stemline Therapeutics Announces Positive Data Presentations on SL-701 and SL-801 at ASCO
|
|
04 Jun 2018 |
SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018
|
|
04 Jun 2018 |
Phase II Clinical Trials of DCVAC Show Significant Benefit for Patients with Ovarian and Lung Cancer
|
|
04 Jun 2018 |
Ichor Medical Systems Announces First in Human Administration with Its Next Generation TriGrid System of a DNA Vaccine for Chronic Hepatitis B in Development
|
|
03 Jun 2018 |
NANT Receives FDA Authorization for New Clinical Trials with Personalized, Next-Generation Neoepitope Cancer Vaccine
|
|
02 Jun 2018 |
Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting
|
|
01 Jun 2018 |
Elios Therapeutics Announces Interim Phase IIb Results of TLPLDC, a Personalized Therapeutic Cancer Vaccine for the Treatment of Melanoma, at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
01 Jun 2018 |
SELLAS Life Sciences Provides Clinical Update on Phase 2b NeuVax™ (nelipepimut-S) Study in Combination with Trastuzumab in HER2 1+/2+ Breast Cancer Patients
|
|
31 May 2018 |
NW Bio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
|
|
28 May 2018 |
CEPI Awards $25 Million Contract to Profectus BioSciences and Emergent BioSolutions to Develop Nipah Virus Vaccine
|
|
25 May 2018 |
SOTIO Starts Phase I/II Trial of DCVAC in Combination with ONCOS-102: The Targovax Adenovirus Based Immunotherapy
|
|
23 May 2018 |
Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
|
|
23 May 2018 |
Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of Probiotic Oral Immunotherapy for the Treatment of Peanut Allergy (PPOIT-003)
|
|
23 May 2018 |
Allergy Therapeutics announces positive top-line results from its Grass MATA MPL Phase II dose ranging study
|
|
23 May 2018 |
MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma
|
|
22 May 2018 |
Inovio Opens Phase 2 Trial for VGX-3100 in Third Indication To Treat HPV – The No. 1 Sexually Transmitted Disease
|
